UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	AL
OMB Number:	3235-028
Estimated average burd	len
hours per response	0.

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

e Responses	s)													
Name and Address of Reporting Person * Salzmann Peter				2. Issuer Name and Ticker or Trading Symbol Immunovant, Inc. [IMVT]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) 320 W 37TH STREET, 3RD FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 12/18/2019						X Officer (give title below) Other (specify below) Chief Executive Officer				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person Form filed by More than One Reporting Person				
<i>i</i>)	(State)	(Zip)				Table	I - Non-De	rivative Securit	ies Acquire	d, Disposed of	, or Benefic	cially Owned		
(Instr. 3) Da		2. Transaction Date (Month/Day/Ye	ear) Exe	ar) any		Code (Instr. 8)		(A) or Disposed Instr. 3, 4 and 5)	Owned Following Rep Transaction(s) (Instr. 3 and 4)			O F D or (I	wnership orm: irect (D) r Indirect)	Nature f Indirect deneficial dwnership finstr. 4)
Report on a s	separate line for each		II - Der	ivati	ve Securitie	es Acq	Persor this for curren	rm are not req tly valid OMB osed of, or Bene	uired to re control nu eficially Ow	spond unles mber.			n SEC 14	74 (9-02)
	nversion Date Execution Exercise (Month/Day/Year) any (Month/Day/Year) (Month/Day/Year)	any	4. Transac Code	ction	5. Number of		6. Date Ex- Expiration	ercisable and Date	7. Title and Underlying	Securities		Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s (Instr. 4)	(I) (Instr. 4)	
\$ 7.86	12/18/2019		A		1,479,04	3	(1)	06/19/2029	Commor Stock	1,479,043	(2)	1,479,043	D	
	Peter TH STRE RK, NY curity Report on a security Conversion or Exercise Price of Derivative Security	Peter (First) TH STREET, 3RD FLOO (Street) RK, NY 10018 (State) Courity Ceport on a separate line for each conversion or Exercise Price of Derivative Security	Peter (Street) (Middle) TH STREET, 3RD FLOOR (Street) RK, NY 10018 (State) (Zip) 2. Transaction Date (Month/Day/Year) Conversion Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year)	Peter Imm (Street) (Middle) 3. Da 12/1 (Street) 4. If A RK, NY 10018 (State) (Zip) (Curity 2. Transaction Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (e.g. Code (Month/Day/Year) 3. Transaction Date (month/Day/Year) (Month/Day/Year) (Month/Day/Year) 3. Code (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Code	Peter Immuno 3. Date of 12/18/20 (Street) 4. If Amer RK, NY 10018 (Zip) (Zip) (Month/Day/Year) (Month/Day/Year) (Amount Amount Amoun	Peter Immunovant, Inc. (First) (Middle) 3. Date of Earliest Tra 12/18/2019 (Street) 4. If Amendment, Date (RK, NY 10018 (State) (Zip) (curity 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Execution Date, if any (Month/Day/Year) 3. Transaction Date (Execution Date, if any (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Transaction Derivative Securities Security (Month/Day/Year) 4. Transaction Date (Instr. 8) 5. Number Code (Instr. 3, 4, 5) Code V (A)	Peter Immunovant, Inc. [IMV of the content of the conversion of Exercise Price of Derivative Security Security Immunovant, Inc. [IMV of the content of the c	Peter	Immunovant, Inc. [IMVT] 3. Date of Earliest Transaction (Month/Day/Year) 12/18/2019 4. If Amendment, Date Original Filed(Month/Day/Year) 12/18/2019 Table I - Non-Derivative Security 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Instr. 8) (Instr. 3, 4 and 5) 2. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Securities Acquired (Month/Day/Year) 4. Sec	Peter Immunovant, Inc. [IMVT] 3. Date of Earliest Transaction (Month/Day/Year) 12/18/2019 4. If Amendment, Date Original Filed(Month/Day/Year) 6. X RK, NY 10018 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) Transaction Date (Month/Day/Year) (Instr. 3, 4 and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 7, 4 and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8) Table II - Derivative Securities Acquired (Instr. 8) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Date (E.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Date (E.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Peter Immunovant, Inc. [IMVT] X Director X Officer (give ii)	Check Chec	Peter	Check all applicable Special Check Special Check Special Check Special Special Check Special Special Check Special Spec

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Salzmann Peter 320 W 37TH STREET, 3RD FLOOR NEW YORK, NY 10018	X		Chief Executive Officer				

Signatures

/s/ W. Bradford Middlekauff, attorney-in-fact for Peter Salzmann	12/20/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.
- In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant (2) Sciences Ltd., the option to purchase 3,024,219 shares of Immunovant Sciences Ltd. at exercise price of \$3.84 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.